Neuvasq Biotechnologies presented its latest work at EBBM 2026.

Public source

Publisher name

Public post

Great to see our latest work heading to EBBM 2026! 🧠 Proud to see Audrey Progneaux presenting our work, go check out her poster if you are there! 👏

Log in to read the full post

Company

Neuvasq Biotechnologies

Advancing innovative Wnt surrogate antibodies to restore blood-CNS barriers.

Industry
Biotechnology
Location
Gosselies, BE
Company size
11–50 employees

About Neuvasq Biotechnologies

Neuvasq Biotechnologies is pioneering the development of first-in-class Gpr124- and Reck-targeting Wnt surrogate antibodies, designed to restore the integrity of the blood-retina and blood-brain barriers. This groundbreaking approach holds the potential to transform treatments and improve the lives of patients with vascular retinopathies – diabetic macular edema (DME) and wet age-related macular degeneration (wAMD) – or severe neurological disorders.

See more

Latest activity

3 signals

Discover more

Similar public activity from other companies.

Customize signals for your business.

Know everything happening across the B2B world, and act on the company movements that matter to you.

© 2026 SeedOpsCompany intelligence.

SeedOps.